148 related articles for article (PubMed ID: 11036954)
1. The clinical pharmacology of alkylating agents in high-dose chemotherapy.
Huitema AD; Smits KD; Mathôt RA; Schellens JH; Rodenhuis S; Beijnen JH
Anticancer Drugs; 2000 Aug; 11(7):515-33. PubMed ID: 11036954
[TBL] [Abstract][Full Text] [Related]
2. Recent advances in the biochemical pharmacology of selected alkylating agents.
Wheeler GP
Transplant Proc; 1973 Sep; 5(3):1167-70. PubMed ID: 4738047
[No Abstract] [Full Text] [Related]
3. Triazene compounds: mechanism of action and related DNA repair systems.
Marchesi F; Turriziani M; Tortorelli G; Avvisati G; Torino F; De Vecchis L
Pharmacol Res; 2007 Oct; 56(4):275-87. PubMed ID: 17897837
[TBL] [Abstract][Full Text] [Related]
4. Medical treatment and other combination regimens.
Bajetta E; Del Vecchio M; Bajetta R; Canova S
Tumori; 2007; 93(3):suppl 22-6. PubMed ID: 17679485
[No Abstract] [Full Text] [Related]
5. Treatment of advanced Hodgkin's disease with (1,3 bis (2-chloroethyl)-1-nitrosourea) BCNU.
Young RC; DeVita VT; Serpick AA; Canellos GP
N Engl J Med; 1971 Aug; 285(9):475-9. PubMed ID: 5558887
[No Abstract] [Full Text] [Related]
6. Bendamustine: mechanism of action and clinical data.
Cheson BD; Leoni L
Clin Adv Hematol Oncol; 2011 Aug; 9(8 Suppl 19):1-11. PubMed ID: 22362008
[TBL] [Abstract][Full Text] [Related]
7. [Mechanisms of action and clinical effectiveness of the newly approved anti-cancer drug bendamustine].
Furukawa Y; Hiraoka N; Wada T; Kikuchi J; Kano Y
Nihon Yakurigaku Zasshi; 2011 Jul; 138(1):26-32. PubMed ID: 21747206
[No Abstract] [Full Text] [Related]
8. The mechanisms of action of antitumor compounds.
Belousova AK
Natl Cancer Inst Monogr; 1977 Mar; (45):183-93. PubMed ID: 73135
[No Abstract] [Full Text] [Related]
9. Nitrosoureas: molecular pharmacology/ translational research.
D'Incalci M
Tumori; 2007; 93(3):suppl 17-21. PubMed ID: 17679484
[No Abstract] [Full Text] [Related]
10. [Toxicodermia by bendamustine: development of a desensization protocol].
Sangrador Pelluz C; Luis Hidalgo MM; Martínez García M; Pérez-Serrano Lainosa MD; Soler Company E
Farm Hosp; 2013; 37(5):421-3. PubMed ID: 24128107
[No Abstract] [Full Text] [Related]
11. Severe CMV reactivation and gastritis during treatment of follicular lymphoma with bendamustine.
Lim SH; Pathapati S; Langevin J; Hoot A
Ann Hematol; 2012 Apr; 91(4):643-4. PubMed ID: 21811782
[No Abstract] [Full Text] [Related]
12. Therapy-related acute myeloid leukemia in a patient with chronic lymphocytic leukemia treated with rituximab-bendamustine.
García-Muñoz R; García DK; Roldán-Galiacho V; Merchante-Andreu M; Campeny-Najara A; Rabasa P
Ann Hematol; 2014 Apr; 93(4):699-702. PubMed ID: 23907409
[No Abstract] [Full Text] [Related]
13. Preliminary study on pharmacokinetics of dacarbazine and fotemustine in glioblastoma multiforme patients does not indicate gender-specific differences.
Fazeny-Dörner B; Mader RM; Piribauer M; Rizovski B; Stögermaier B; Marosi C
Anticancer Drugs; 2004 Jun; 15(5):495-8. PubMed ID: 15166624
[TBL] [Abstract][Full Text] [Related]
14. Alkylating agents, nitrosoureas and alkyltriazenes.
Connors TA
Cancer Chemother Biol Response Modif; 1987; 9():23-35. PubMed ID: 3079405
[No Abstract] [Full Text] [Related]
15. Therapeutic journery of nitrogen mustard as alkylating anticancer agents: Historic to future perspectives.
Singh RK; Kumar S; Prasad DN; Bhardwaj TR
Eur J Med Chem; 2018 May; 151():401-433. PubMed ID: 29649739
[TBL] [Abstract][Full Text] [Related]
16. Carcinogenicity of alkylating cytostatic drugs in animals.
Berger MR
IARC Sci Publ; 1986; (78):161-76. PubMed ID: 3583389
[No Abstract] [Full Text] [Related]
17. FIVB--a new combination of drugs in the treatment of cancer.
Van Eden EB; Falkson G; Van der Merwe AM; Van Dyk JJ; Falkson HC
S Afr Med J; 1973 Jun; 47(23):982-4. PubMed ID: 4714282
[No Abstract] [Full Text] [Related]
18. Modulating effect of new potential antimelanomic agents, spin-labeled triazenes and nitrosoureas on the DOPA-oxidase activity of tyrosinase.
Gadjeva V; Zheleva A; Raikova E
Cancer Biochem Biophys; 1999 Jul; 17(1-2):99-108. PubMed ID: 10738906
[TBL] [Abstract][Full Text] [Related]
19. Phase II trial of temozolomide plus concurrent whole-brain radiation followed by TNV regimen as adjuvant therapy for patients with newly diagnosed primary CNS lymphoma.
Wang Y; Liu B; Xu D; Zhao H; Zhu Y; Xu J; Tao R
Neurol India; 2013; 61(3):260-4. PubMed ID: 23860145
[TBL] [Abstract][Full Text] [Related]
20. Secondary acute lymphoblastic leukaemia following oxaliplatin for adjuvant chemotherapy in colon cancer.
Merlin F; Prochilo T; Kildani B; Tucci A; Ferrari S; Rossi G; D'Adda P; Beretta GD
Acta Oncol; 2008; 47(3):464-6. PubMed ID: 17851873
[No Abstract] [Full Text] [Related]
[Next] [New Search]
